Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
ARTW Art's Way Manufacturing Co Inc

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-0.2236 (-9.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 168,460 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.


FRSH DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alerts Freshworks Inc. (FRSH) Investors of Today's Deadline in Securities Class Action

1:27 pm ET January 3, 2023 (Globe Newswire) Print
FRSH DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alerts Freshworks Inc. (FRSH) Investors of Today's Deadline in Securities Class ActionGlobeNewswireJanuary 03, 2023

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Freshworks Inc. (NASDAQ: FRSH) investors who suffered significant losses to submit your losses now.

Defined Class: Purchasers in Freshworks Inc.'s Sept. 21, 2021 IPO

Lead Plaintiff Deadline: Jan. 3, 2023

Contact An Attorney


Freshworks Inc. (NASDAQ: FRSH) Securities Class Action:

The litigation focuses on Defendants' misrepresentations and omissions in connection with Freshworks' September 2021 initial public offering ("IPO"), wherein the company sold 28.5 million shares at $36 per share raising over $1 billion in gross proceeds.

Specifically, Freshworks' IPO registration statement repeatedly touted the company's marked increases in its "net dollar retention rate" (the measure of the rate of expansion within its customer base) and in its year-over-year revenue growth rate.

According to the complaint, the IPO registration statement misled investors since it failed to disclose the company's business had encountered significant obstacles, causing Freshworks' net dollar retention rate to plateau and its revenue growth rate and billings to decelerate.

The truth began to reach the market on Feb. 10, 2022, when the company reported Q4 2021 earnings, which included flat calculated billings growth and revenue growth deceleration. In response, the price of Freshworks shares fell approximately 18%.

Then, on May 3, 2022 Freshworks announced its Q1 2022 earnings, which included another quarter of decelerating revenue growth and billings that missed consensus estimates. In response, the price of Freshworks shares fell again.

By the commencement of the action, the stock traded as low as $10.51 per share, a 70% decline from its IPO price.

"We're focused on investors' losses and proving Freshworks misled investors about its slowing growth," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Freshworks and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Freshworks should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.


Reed Kathrein, 844-916-0895

Primary Logo

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.